CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

VOLUNTARY ANNOUNCEMENT
CLINICAL RESEARCH RESULTS OF A RANDOMIZED, BLINDED AND PARALLEL CONTROLLED CLINICAL STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF HETEROLOGOUS BOOSTING WITH COVID-19 MRNA VACCINE IN ADULTS AGED 18 YEARS AND ABOVE WHO HAVE RECEIVED THREE DOSES OF COVID-19 INACTIVATED VACCINE

This announcement is made by CanSino Biologics Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The Company is pleased to announce that, the Group's COVID-19 mRNA vaccine CS-2034 (the "**CS-2034**") has achieved positive interim data in a clinical trial evaluating the safety and immunogenicity of the heterologous CS-2034 booster.

BASIC INFORMATION ABOUT THE PRODUCT

CS-2034 is a COVID-19 mRNA vaccine with protection against existing variants. Results of pre-clinical studies showed that, such vaccine can induce high-titer neutralizing antibodies against multiple SARS-CoV-2 variants of concern identified by the World Health Organization. Compared with the original strain-based COVID-19 vaccines, CS-2034 can elicit neutralizing antibodies with better cross-variant reactivity, and is expected to provide more effective protection against infections caused by circulating variants.

To date, CS-2034 is in phase IIb clinical trial stage, and its current progress is in line with expectations. The next stage of research and development work will be planned according to future epidemic situation, national immunization strategy, review policies and the positive clinical data obtained so far.

CLINICAL STUDIES AND PRINCIPAL RESULTS

The research is a randomized, blinded and parallel controlled clinical study to evaluate the safety and immunogenicity of heterologous boosting with CS-2034 in adults aged 18 years and above who have received three doses of COVID-19 inactivated vaccine. The clinical trial started in October 2022 in Jiangsu province, and is in active long-term follow-up period. A total of 433 adults who had received 3 doses of the COVID-19 inactivated vaccine at least 6 months ago were enrolled in the trial and were divided into 2 groups, namely group A and group B. The participants in group

A were further divided into 2 age subgroups, one with adults aged 18-59 years and the other with adults over 60 years (160 participants each), and randomized at a 3:1 ratio to receive a dose of CS-2034 (0.3 ml volume per dose) or COVID-19 inactivated vaccine (0.5 ml volume per dose). Systematic safety observation for all participants was conducted for 28 days post vaccination and blood specimens were collected on Day 0, 7, 14, 28, Month 3 and 6 after the boost for the immunogenicity assessment. A total of 113 participants at least 60 years of age were enrolled in group B and received a dose of CS-2034 for safety analysis.

1. Safety

The analysis of the safety data within 28 days after the booster shows that heterologous CS-2034 booster has a favorable safety profile in people who had received three doses of COVID-19 inactivated vaccine previously. The overall incidence of adverse events was mainly mild in severity. The incidence rate and severity of the adverse events of CS-2034 were significantly lower than those of the commercialized mRNA vaccines, according to literature reports. The safety profile of elderly participants is better than that of participants aged 18-59 years.

2. Immunogenicity

The geometric mean titers (GMTs) of the live-virus neutralizing antibodies, on Day 28 post CS-2034 boost, were 877 against original strain, and 293 against Omicron BA.1 variant, which were 27 and 23 times as high as those in the inactivated vaccine group, respectively.

The dynamics of cross-reactive neutralizing antibody against the current circulating Omicron BA.5 variant were measured, and we found that the neutralizing antibody titer peaked (GMT = 407) at 7 days post CS-2034 boost, which was 29 times as high as that of homologous inactivated vaccine boost. The GMT of neutralizing antibody titer in elderly participants on Day 7 post CS-2034 boost was 296 against BA.5 variant, which was 23 times as high as that of homologous inactivated vaccine boost.

We cannot guarantee that we will ultimately develop or commercialize CS-2034 successfully. Considering several unpredictable factors in the process of clinical trials and the results and timing of clinical trials, evaluations and approvals are subject to uncertainty. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, January 5, 2023

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive directors.